NeuroBo Pharmaceuticals GAAP EPS of -$2.46
Seeking Alpha News (Thu, 28-Mar 3:02 PM ET)
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
PRNewswire (Thu, 28-Mar 8:01 AM ET)
PRNewswire (Wed, 13-Mar 8:01 AM ET)
PRNewswire (Mon, 4-Mar 8:01 AM ET)
PRNewswire (Thu, 29-Feb 8:01 AM ET)
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
PRNewswire (Mon, 12-Feb 8:01 AM ET)
PRNewswire (Thu, 1-Feb 8:01 AM ET)
PRNewswire (Thu, 18-Jan 8:01 AM ET)
NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
PRNewswire (Tue, 9-Jan 8:30 AM ET)
NeuroBo to Participate in Industry and Investor Conferences in January
PRNewswire (Tue, 2-Jan 8:01 AM ET)
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused primarily on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes (T2D): DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
Neurobo Pharmaceuticals trades on the NASDAQ stock market under the symbol NRBO.
As of March 28, 2024, NRBO stock price declined to $4.09 with 33,811 million shares trading.
NRBO has a beta of 0.57, meaning it tends to be less sensitive to market movements. NRBO has a correlation of 0.01 to the broad based SPY ETF.
NRBO has a market cap of $19.84 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, NRBO stock traded as high as $1,576.82 and as low as $2.89.
The top ETF exchange traded funds that NRBO belongs to (by Net Assets): VXF, DFAS, DFAT.
NRBO has underperformed the market in the last year with a price return of -23.7% while the SPY ETF gained +33.6%. However, in the short term, NRBO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +23.9% vs +10.1% return in SPY. But in the last 2 weeks, NRBO shares have been beat by the market, returning -8.5% compared to an SPY return of +1.7%.
NRBO support price is $4.07 and resistance is $4.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRBO stock will trade within this expected range on the day.